Monoclonal antibody (mAb)-based cancer therapy

Is it time to reevaluate dosing strategies?

Margaret A. Lindorfer, Adrian Wiestner, Clive S. Zent, Ronald P. Taylor

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.

Original languageEnglish (US)
Pages (from-to)959-961
Number of pages3
JournalOncoImmunology
Volume1
Issue number6
DOIs
StatePublished - 2012

Fingerprint

Monoclonal Antibodies
Neoplasms
Therapeutics

Keywords

  • CD20 mAbs
  • Immunomonitoring
  • Therapeutic antibodies
  • Therapeutic trials
  • Trogocytosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Monoclonal antibody (mAb)-based cancer therapy : Is it time to reevaluate dosing strategies? / Lindorfer, Margaret A.; Wiestner, Adrian; Zent, Clive S.; Taylor, Ronald P.

In: OncoImmunology, Vol. 1, No. 6, 2012, p. 959-961.

Research output: Contribution to journalArticle

Lindorfer, Margaret A. ; Wiestner, Adrian ; Zent, Clive S. ; Taylor, Ronald P. / Monoclonal antibody (mAb)-based cancer therapy : Is it time to reevaluate dosing strategies?. In: OncoImmunology. 2012 ; Vol. 1, No. 6. pp. 959-961.
@article{98123c5da4274dee812c2224f4d4e238,
title = "Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?",
abstract = "Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.",
keywords = "CD20 mAbs, Immunomonitoring, Therapeutic antibodies, Therapeutic trials, Trogocytosis",
author = "Lindorfer, {Margaret A.} and Adrian Wiestner and Zent, {Clive S.} and Taylor, {Ronald P.}",
year = "2012",
doi = "10.4161/onci.20368",
language = "English (US)",
volume = "1",
pages = "959--961",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Monoclonal antibody (mAb)-based cancer therapy

T2 - Is it time to reevaluate dosing strategies?

AU - Lindorfer, Margaret A.

AU - Wiestner, Adrian

AU - Zent, Clive S.

AU - Taylor, Ronald P.

PY - 2012

Y1 - 2012

N2 - Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.

AB - Compelling evidence indicates type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune efector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more efective.

KW - CD20 mAbs

KW - Immunomonitoring

KW - Therapeutic antibodies

KW - Therapeutic trials

KW - Trogocytosis

UR - http://www.scopus.com/inward/record.url?scp=84880983195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880983195&partnerID=8YFLogxK

U2 - 10.4161/onci.20368

DO - 10.4161/onci.20368

M3 - Article

VL - 1

SP - 959

EP - 961

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 6

ER -